Strategic Expansion with AI and Spectral Technology

Shanghai, China, 15th Jan 2026 – Global AI spectral skin technology company VitaOptix (UK) today announced two strategic milestones: the launch of its Asia-Pacific R&D Center in Shanghai, China, and the opening of its Bangkok Market Operations Center in Thailand. These developments mark the company’s entry into the Southeast Asian market.
Alongside this expansion, VitaOptix introduced Otica, a specialized intimate health brand. The brand is scheduled to introduce an AI Intimate Detection System and Pelvic Floor Magnetic Therapy Solution to the Thai market to provide standardized women’s health management options.

Infrastructure Development: China R&D Center and Thailand Hub
The Shanghai base serves as the first overseas R&D center for VitaOptix, focusing on the development of AI spectral algorithms and clinical validation systems. The facility is staffed by a 30-member interdisciplinary team, including optical engineers, biologists, and AI specialists. Dr. Chen, Head of the Center, stated: “We are adapting the AI spectral technology from our skin analyzers to gynecological detection scenarios to enhance diagnostic precision in the intimate health sector.” The development of the next-generation AI multimodal detection robot, Intima AI Robot, is led by this center and is scheduled for release in 2026.
Based in Bangkok, the Thailand Market Operations Center provides localized services and plans to collaborate with medical aesthetics institutions. Dr. Stefan Müller, Founder of VitaOptix, stated: “Thailand’s annual medical tourism revenue exceeds $7 billion. We chose to establish a foothold here due to its mature private healthcare network and open policy environment, making it a strategic pivot to tap into the 600-million-person ASEAN market.”

Otica Brand: Integration of Technology in Health Management
Utilizing technical resources from the China R&D Center, VitaOptix launched the Otica brand, applying AI spectral technology to female health management. The brand’s technology suite focuses on non-invasive assessment and rehabilitation support.
The product line includes an AI Intimate Detection Device that utilizes multi-spectral imaging and AI deep learning for the assessment of female health indicators. For rehabilitation, the brand offers a Pelvic Floor Magnetic Therapy Device, which employs targeted electromagnetic pulses and biofeedback to support pelvic organ recovery. Additionally, Otica provides health care solutions combining EMS and SPA regulation therapy for tissue management and care.
“Traditional gynecological exams often rely on invasive methods, whereas Otica’s AI spectral detection completes an assessment in 3 minutes,” said Dr. Chen.

Market Context: Health Management Trends
This expansion represents the transition of VitaOptix from skin detection to deep tissue health management. Market observations from Frost & Sullivan indicate that the intimate health sector is experiencing growth exceeding 25% annually. The application of AI spectral technology establishes a technical barrier for the Otica brand, while the establishment of the Thailand center is expected to facilitate procurement processes for beauty institutions across Southeast Asia.
 

Media Contact

Organization: Shanghai VitaOptix Technology Co., LTD.

Contact Person: Stefan

Website: https://www.vitaoptix.com/

Email: Send Email

City: Shanghai

Country:China

Release id:40195

Disclaimer: This content includes references to health-related technologies and is provided for general informational purposes only. It does not constitute medical, diagnostic, or therapeutic advice, nor does it make claims regarding clinical outcomes or effectiveness.

The post VitaOptix Asia Pacific Business Expansion and Otica Brand Launch appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

LONDON, UK, 15th January 2026, ZEX PR WIRE, Stelios Tzellos, Ph.D., is the co-author of multiple peer-reviewed research studies focused on gene regulation by the Epstein-Barr virus (EBV), particularly the molecular differences between EBV type 1 and type 2 strains. His contributions to the field of viral oncology and transcriptional regulation were developed during his doctoral training at Imperial College London, where he earned a Ph.D. in Molecular Biology following undergraduate and master’s degrees in Biochemistry.

His work has been published in journals such as the Journal of General Virology, where he is listed as first author on the 2014 study titled “EBV EBNA-2 type 1 and type 2 proteins induce expression of the cellular CXCR7 and EBI2 genes through a mechanism involving a common motif in their transactivation domains.” This study is indexed in PubMed under PMID 25436768.

The study investigates how a single amino acid substitution (S442D) in the EBNA-2 protein from EBV type 2 can convert it to a phenotype more similar to that of type 1 EBNA-2, which is more efficient at transforming B cells. The findings contribute to the understanding of how sequence variation in viral proteins can lead to differences in their ability to activate both viral and host cell genes involved in cell proliferation and transformation.

The researchers found that type 1 EBNA-2 induced stronger activation of the viral LMP-1 gene and the cellular CXCR7 gene, both of which are associated with enhanced B-cell growth and survival. Using chromatin immunoprecipitation (ChIP) assays, the study showed that type 1 EBNA-2 had stronger binding to regulatory regions of these genes compared to type 2 EBNA-2. Motif analysis identified an ETS-IRF composite element that may account for these differences in transcriptional activation.

This work adds to the field’s understanding of how EBV contributes to the development of lymphoproliferative diseases and certain types of cancer. The research has implications for the study of viral oncogenesis and may inform future therapeutic approaches that target EBV-mediated signaling pathways.

In addition to the 2014 study, Stelios Tzellos is listed as a co-author on other EBV-related publications that investigate the molecular basis of differential gene activation by EBNA-2. These include contributions to studies that used 5′ RACE to identify transcription start sites in EBNA-2-regulated genes and that evaluated how amino acid changes influence protein-DNA interactions at key promoter regions.

During his time at Imperial College London, Dr. Tzellos worked in a laboratory environment applying molecular biology techniques such as site-directed mutagenesis, luciferase reporter assays, and chromatin immunoprecipitation to explore these mechanisms. His work involved generating and testing EBNA-2 variants to better understand how small sequence changes can result in functional differences in gene expression.

Although he transitioned to a career in pharmaceutical analytics and forecasting after completing his Ph.D., Dr. Tzellos’ academic work continues to be cited in molecular virology and EBV-related research. His publications remain part of the foundational literature exploring the transcriptional control functions of EBV nuclear antigens and their relevance to B-cell biology.

For access to the full publication, readers may refer to:
PubMed: PMID 25436768

Dr. Tzellos currently resides in the United Kingdom and continues to work in the pharmaceutical sector in analytics roles. His early scientific work in viral gene regulation continues to inform his approach to evidence evaluation and scientific rigor.

• Florida-based sales leader Jared Rudnick outlines a simple, realistic plan designed for individuals with limited time, focus, and bandwidth.

Florida, US, 15th January 2026, ZEX PR WIRE, Many professionals know what they should be doing, but struggle to find the time to do it consistently. Jared Rudnick, partner at RMS Sales, believes the problem isn’t effort—it’s overcomplication. Drawing on decades of experience in sales and entrepreneurship, Rudnick has outlined a practical plan for people with limited time and attention.

“Most people don’t need a new strategy,” Rudnick says. “They need a smaller one they’ll actually follow.”

Recent data shows why this matters. Studies indicate that over 40% of professionals feel constantly behind on follow-up, while average sales cycles have increased by 18–25% across manufacturing and related industries. Add in the fact that buyers now take 60% longer to approve new vendors, and the cost of inaction becomes clear.

“You can’t control the market,” Rudnick says. “But you can control what you do with the time you have.”

The 10-Minute Daily Plan

Best for busy weekdays

Steps:

• Write down one call, one follow-up, and one note for tomorrow
  

• Send one check-in email to an existing contact
  

• Review yesterday’s single most important task
  

Expected outcome:
Momentum. “When you feel overwhelmed, start small,” Rudnick says. “One action usually leads to the next.”

The 30-Minute Focused Plan

Best for mornings or lunch breaks

Steps:

• Review your top three accounts or relationships
  

• Make two direct outreach attempts (call or email)
  

• Write one handwritten or digital note outlining next steps
  

Expected outcome:
Consistency. “Effort compounds,” Rudnick says. “Missing a goal taught me that more calls and more presence matter.”

The 2-Hour Weekend Reset Plan

Best for regaining clarity

Steps:

• Review the past week and identify what actually worked
  

• Write where you want to be in 1, 3, and 5 years
  

• Clean up your contact list and flag dormant relationships
  

• Plan next week’s top five actions
  

Expected outcome:
Direction. “You don’t need perfect balance,” Rudnick says. “You need a clear direction.”

What to Avoid

Rudnick cautions against a few common mistakes:

• Overplanning instead of acting
  

• Waiting for motivation
  

• Chasing shortcuts or automation too early
  

• Ignoring follow-up
  

• Comparing progress to others
  

“Balance shifts,” he says. “Trying to hold everything steady usually leads to burnout.”

Why This Approach Works

Rudnick’s approach reflects how he built his own career—from award-winning sales performance to co-founding RMS Sales. “There are years you grow and years you learn,” he says. “Both matter.”

He believes simple, repeatable actions are more powerful than complex systems. “Take care of the little things,” Rudnick adds. “The bigger things follow.”

Call to Action

Rudnick encourages readers to start today—not next week—by choosing the 10-minute plan and completing it once. “Don’t wait for clarity,” he says. “Action creates it.”

About Jared Rudnick
Jared Rudnick is a Florida-based partner at RMS Sales with more than 20 years of experience in electronics manufacturing representation. He is known for his disciplined, long-term approach to sales, leadership, and building businesses through consistent effort and practical habits.